EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Sarah M McLeod iD, John P O'Donnell iD, Navaneeth Narayanan iD, John P Mills iD, Keith S Kaye iD

Future Microbiology · 02.05.2024 · 19 (7) · 563-576

DOI: 10.2217/fmb-2023-0248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Microbiology, 2024-03. Verfasst von Sarah M McLeod und 4 weiteren Autor:innen. Beteiligte Einrichtung: Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, beta-Lactamase Inhibitors, Acinetobacter Infections. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against Acinetobacter but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both in vitro and in vivo against multidrug-resistant ABC. Sulbactam-durlobactam is a promising alternative therapy for the treatment of serious Acinetobacter infections, which can have high rates of mortality. Sulbactam–durlobactam: a drug for treating lung infectionsAcinetobacter is a type of bacteria. One type, called CRAB, causes serious infections and can be fatal. CRAB is very hard to treat because most drugs no longer work. Sulbactam–durlobactam (SUL-DUR) is a drug that can kill CRAB. The US FDA approved SUL-DUR in May of 2023 for treating lung infections (pneumonia) caused by CRAB. This article explains how SUL-DUR works. Use of SUL-DUR and other drugs to treat these types of infections are discussed. In conclusion, SUL-DUR is a promising therapy for serious infections caused by CRAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiSulbactambeta-Lactamase InhibitorsAcinetobacter InfectionsAzabicyclo CompoundsAnti-Bacterial AgentsHumansDrug Resistance, Multiple, Bacterialbeta-Lactamasesbeta-LactamsMicrobial Sensitivity TestsDrug CombinationsAnimals

Stichwörter der Autor:innen

Acinetobacter baumanniicarbapenem resistancepneumoniasulbactam–durlobactamβ-lactamase inhibitor

Substanzen

Sulbactambeta-Lactamase InhibitorsAzabicyclo CompoundsAnti-Bacterial Agentsdurlobactambeta-Lactamasesbeta-LactamsDrug Combinations

Autor:innen und Institutionen

  • Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Rutgers University Ernest Mario School of Pharmacy, Department of Pharmacy Practice & Administration, Piscataway, NJ 08901, USA.
  • Division of Allergy, Immunology & Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.

ORCID-Profile: Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye

Förderung

  • NIAID NIH HHS

Zitieren

APA

McLeod, S. M., O'Donnell, J. P., Narayanan, N., Mills, J. P., & Kaye, K. S. (2024). Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. Future Microbiology, 19(7), 563-576. https://doi.org/10.2217/fmb-2023-0248

Vancouver

McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS. Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. Future Microbiology. 2024;19(7):563-576. doi:10.2217/fmb-2023-0248

BibTeX
@article{McLeod2024,
  author = {McLeod, Sarah M and O'Donnell, John P and Narayanan, Navaneeth and Mills, John P and Kaye, Keith S},
  title = {Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii},
  journal = {Future Microbiology},
  year = {2024},
  volume = {19},
  number = {7},
  pages = {563--576},
  doi = {10.2217/fmb-2023-0248}
}
Kostenlos starten →